Working… Menu

Transferrin Saturation and Asthenia in Hemochromatosis (HEMOSAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03356548
Recruitment Status : Completed
First Posted : November 29, 2017
Last Update Posted : July 31, 2019
Information provided by (Responsible Party):
Rennes University Hospital

Brief Summary:
Observational study.

Condition or disease
Hemochromatoses, Genetic

Detailed Description:

The linked HFE genetic hemochromatosis (C282Y mutation in the homozygous state) is the most common form of genetic iron overload.

Its treatment is based on bloodletting, and takes place in 2 phases, according to the recommendations of the High Authority of Health (HAS). The first phase, called induction, aims to achieve ferritinemia <50 by performing weekly bleeds.

The second phase, called maintenance, aims to maintain this ferritinemia <50 by performing bleeding every 1 to 6 months depending on the case.

The treatment is therefore according to the current recommendations only adapted according to ferritinemia, and not according to the effectiveness on the functional symptoms. However, some patients report persistent asthenia during maintenance treatment, despite ferritin levels <50. This could reflect an incomplete control of their disease, and leads us to raise two points:

  • It is known that in some subjects, the Transferrin Saturation Coefficient remains high, despite ferritinemia <50; it is also known that this elevation of the Transferrin Saturation Coefficient may be accompanied by a rise in circulating free iron, which is toxic for the organism1.
  • The asthenia observed in some patients in the maintenance phase could be linked to a high rate of Transferrin Saturation Coefficient.

Our objective is to evaluate, in patients homozygous C282Y in maintenance phase, the association between quality of life and Transferrin Saturation Coefficient .

Layout table for study information
Study Type : Observational
Actual Enrollment : 260 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Study of the Association Between Transferrin Saturation and Asthenia in Hemochromatosis
Actual Study Start Date : April 10, 2017
Actual Primary Completion Date : April 9, 2019
Actual Study Completion Date : April 9, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hemochromatosis

Primary Outcome Measures :
  1. Quality of life questionnaire SF 36 [ Time Frame: Through study completion, an average of 3 months ]
  2. Biological markers : Transferrin Saturation Coefficient [ Time Frame: Through study completion, an average of 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with genetic hemochromatosis HFE
  • Inclusion criteria:

    • homozygous C282Y ;
    • in the maintenance phase for at least 6 months ;
    • follow-up at Rennes University Hospital ;
    • patient who has not expressed his opposition to participate in the study.
  • Exclusion criteria:

    • Permanent: any cause of modification of the CST unrelated to hemochromatosis (chronic inflammatory disease, excessive consumption of alcohol ...) ;
    • Temporary: infectious syndrome within 7 days before bleeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03356548

Layout table for location information
Rennes University Hospital
Rennes, Britain, France, 35033
Sponsors and Collaborators
Rennes University Hospital
Layout table for investigator information
Principal Investigator: Fabrice LAINE Rennes University Hospital

Layout table for additonal information
Responsible Party: Rennes University Hospital Identifier: NCT03356548     History of Changes
Other Study ID Numbers: 35RC17_3067_HEMOSAT
First Posted: November 29, 2017    Key Record Dates
Last Update Posted: July 31, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Metal Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Iron Overload
Iron Metabolism Disorders
Metabolic Diseases
Signs and Symptoms